Alembic Pharma Shares Surge After USFDA Nod For New Ovarian Cancer Drug

Alembic Pharmaceuticals receives US FDA approval for Doxorubicin Hydrochloride Liposome injection - Express Pharma

Alembic Pharmaceuticals announced that it has received final approval from the United States Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection. The approval includes 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials. The product is therapeutically equivalent to the reference listed drug (RLD), Doxil Liposome Injection, in the same strengths, markete…

Alembic Pharmaceuticals zooms on getting final nod for Doxorubicin Hydrochloride Liposome Injection

Alembic Pharmaceuticals is currently trading at Rs. 1078.25, up by 106.40 points or 10.95% from its previous closing of Rs. 971.85 on the BSE. The scrip opened at Rs. 1029.75 and has touched a high and low of Rs. 1089.80 and Rs. 990.20 respectively. So far 97681 shares were traded on the counter. The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 1296.15 on 09-Oct-2024 and a 52 week low of Rs. 725.60 on 03-Mar-2025. La…

Alembic Pharma Shares Surge After USFDA Nod For New Ovarian Cancer Drug

Alembic Pharmaceuticals Ltd.'s shares surged over 12% to a nearly six-month high after the company received final approval from the US regulator for its new drug application to treat ovarian cancer and other ailments.The US Food & Drug Administration approved the abbreviated new drug application for Doxorubicin Hydrochloride Liposome injection and single-dose vials, as per a regulatory filing.The approved ANDA is therapeutically equivalent to th…